Home › Funds › Sio Capital Management, LLC › AQST
Sio Capital Management, LLC position in AQST
AQUESTIVE THERAPEUTICS INC COM · Health Care
Sio Capital Management, LLC reported holding 1,486,175 shares of AQST (AQUESTIVE THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$6.2M, representing 1.02% of its reported portfolio and ranking #32 among its reported holdings. Sio Capital Management, LLC has disclosed AQST holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sio Capital Management, LLC's AQST position evolved
Sio Capital Management, LLC first disclosed a stake in AQST in Q1 2025 at 391,629 shares (US$1.1M). The position peaked in Q3 2025 at 1,498,095 shares, worth US$8.4M. Across 6 filings, Sio Capital Management, LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,486,175 shares valued at US$6.2M — a reduction of -436,712 shares quarter over quarter.. Notable position changes include a 142% increase in Q2 2025 (shares rose 69% over the following quarter), a 58% increase in Q3 2025 (shares rose 16% over the following quarter), a 94% increase in Q1 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 391.63K | $1.14M | New |
| Q2 2025 | 947.49K | $3.14M | Add |
| Q3 2025 | 1.50M | $8.37M | Add |
| Q4 2025 | 993.10K | $6.42M | Reduce |
| Q1 2026 | 1.92M | $7.98M | Add |
| Q2 2026 | 1.49M | $6.18M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AQST and 13F data
AQST (AQUESTIVE THERAPEUTICS INC COM) is a Health Care company. 40 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$40.8M), Samsara BioCapital, LLC (US$10.4M), Propel Bio Management, LLC (US$6.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AQST
- Bratton Capital Management, L.P. 9.81M sh · $40.81M · Q2 2026
- Samsara BioCapital, LLC 2.50M sh · $10.40M · Q2 2026
- Propel Bio Management, LLC 1.44M sh · $6.00M · Q2 2026
- Blue Owl Capital Holdings LP 942.93K sh · $3.92M · Q2 2026
- DAFNA Capital Management LLC 645.91K sh · $2.69M · Q2 2026
- Everstar Asset Management, LLC 611.94K sh · $2.55M · Q2 2026
- Bracebridge Capital, LLC 459.22K sh · $1.91M · Q2 2026
More on Sio Capital Management, LLC
FAQ
How long has Sio Capital Management, LLC held AQST?
Sio Capital Management, LLC has disclosed AQST holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is Sio Capital Management, LLC's current position in AQST?
As of Q2 2026, Sio Capital Management, LLC holds 1.49M shares of AQST (AQUESTIVE THERAPEUTICS INC COM), valued at $6.18M, representing 1.02% of its reported portfolio and ranking #32.
Has Sio Capital Management, LLC been buying or selling AQST?
In the latest 13F filing (Q2 2026), Sio Capital Management, LLC reduced its position in AQST. The position peaked in Q3 2025 at 1.50M shares.
Which other funds hold AQST?
Other major institutional holders of AQST include Bratton Capital Management, L.P., Samsara BioCapital, LLC, Propel Bio Management, LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.